InCarda Therapeutics, Inc.
NEWARK, CA · Founded 2009 · CIK 0001552622 · Biotech · Private
Cardiac arrhythmia drugs designed to restore normal sinus rhythm
incardatherapeutics.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $66M
- 5 Form D · Oct 2020
- 72 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 10 granted · 30 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20122014201620182020
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $310,000 | |
| Private capital raised | Form D · SEC | $155,854 | |
| Private capital raised | Form D · SEC | $2,135,000 | |
| Private capital raised | Form D · SEC | $35,296,018 | |
| Private capital raised | Form D · SEC | $27,993,423 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1851 | Kymera Therapeutics | — | — |
| 1852 | VERSAPEUTICS INC | — | $3.8M |
| 1853 | TBC I LLC | — | $1.0M |
| 1854 | InCarda Therapeutics, Inc. | — | $66M |
| 1855 | Recombinetics, Inc. | — | $45M |
| 1856 | Dracen Pharmaceuticals, Inc. | — | $19M |
| 1857 | Ibex Investment Holdings II LLC | — | $1.0M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Isaac ChengDirector
- Johan ChristensonDirector
- Grace ColonDirector · Executive Officer
- Alan ColowickDirector
- Andrew ElBardissiDirector
- Rangachari NarasimhanDirector · Executive Officer
- Bischofberger NorbertDirector
- John PattonDirector · Executive Officer
- McCarthy ReenieDirector
- Miller SamanthaExecutive Officer
- Carlos SchulerDirector · Executive Officer
- Dan WelchDirector
Patents
- Antiarrhythmic Formulationapplication
- Antiarrhythmic Formulationgranted
- Kits And Methods For Induction Of Cardioversion In Subjects With Atrial Arrhythmiasgranted
- Inhaled Therapy For Cardiac Arrhythmiaapplication
- Kits And Methods For Induction Of Cardioversion In Subjects With Atrial Arrhythmiasgranted
- Unit Doses, Aerosols, Kits, And Methods For Treating Heart Conditions By Pulmonary Administrationapplication
- Methods For Diagnosing Brugada Syndrome Using An Aerosolapplication
- Antiarrhythmic Formulationgranted
- Novel Antiarrhythmic Formulationgranted
- Novel Method To Slow Ventricular Rategranted
- Unit Doses, Aerosols, Kits, And Methods For Treating Heart Conditions By Pulmonary Administrationapplication
- Unit Doses, Aerosols, Kits, And Methods For Treating Heart Conditions By Pulmonary Administrationapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.